With an all-stock deal, Harvest One Cannabis Inc (OTCMKTS: HRVOF) acquired Delivra Corp. gaining access to their LivRelief brand, which is a transdermal delivery system that can pass pharmaceutical molecules through the skin. LivRelief is available in Walmart and Shoppers in the United States and Canada as well as in international storefronts. The stock has traded relatively flat on the OTC and on the TSX since the announcement, but investors may be sleeping on this company for some of the more well known names.
“The acquisition of Delivra by Harvest One puts further emphasis on the Harvest One goal of being a leading house of brands in the global health, wellness, and self-care sector. The addition of LivRelief™, which is already on retail shelves across Canada , will give Harvest One a head start for cannabis-infused products in Canada and beyond and is a great addition to our existing brands in this space with Satipharm CBD GelPell capsules already on sale in Europe , and our Dream Water all natural sleep aid available across North America ” said Grant Froese , CEO of Harvest One. Mr. Froese added, “We are very excited to welcome Dr. Joseph Gabriele and the Delivra team into the Harvest One family and expanding our brand portfolio, as well as moving forward aggressively with our cannabis-infused products strategy when and where legal.”
Harvest One Cannabis Inc (OTCMKTS: HRVOF) develops and provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. It operates through three segments: Cultivation, Medical and Nutraceutical, and Consumer. The company cultivates and distributes cannabis; and processes, manufactures, and distributes cannabis-based food supplement products in Europe. It is also involved in the marketing, distribution, and product development of liquid sleep shots and sleep powder packets. Harvest One Cannabis Inc. is headquartered in Vancouver, Canada.
Find out when $HRVOF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The CEO and Chief Science Officer of Delivra, Dr. Joseph Gabriele, was ecstatic.
“Combined with our proprietary transdermal delivery system platform and extensive research, development and commercialization capabilities, the combined company is extremely well-positioned to take advantage of the growing market for topicals, sprays, beverages, and other cannabis/CBD-infused products,” Dr. Gabriele stated in the joint press release. “In addition, Harvest One’s global reach can provide greater distribution capabilities for our existing product portfolio. This is a value-maximizing transaction that provides our shareholders with a significant premium and an exciting opportunity to participate in the upside of Harvest One. We believe that Harvest One is the ideal partner to take Delivra to the next level.”
As long as the approvals go through, the $14.22 million deal gives Delivra shareholders 13.4% ownership of HRVOF.
As a whole Harvest One has a very expansive portfolio and for a smaller cannabis operator might be under-valued. For example, Delta 9 NINE trades about double the price of Harvest One, but both have a similar profile except Harvest One’s expansion plan is almost three times the size of Delta 9 – and, by all accounts, Harvest One has much more cash in hand.
Harvest One Cannabis Inc (OTCMKTS: HRVOF) has a market cap of 95.21M and a float of 126.4M. HRVOF has quarterly revenue growth cresting over 76,000%. The company is starting to become profitable and this will only aid their expansion plans. Sign-up for continuing coverage on shares of $HRVOF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $HRVOF, either long or short, and we have not been compensated for this article.